Myriad Genetics down 5%, prices $110M stock
…
15,209$
-3,01%
Echtzeit-Aktienkurs Myriad Genetics Inc.
Bid:
Ask:
Nachrichten zur Myriad Genetics Inc. Aktie
Myriad Genetics Announces Pricing of Upsized Offering of Common Stock
SALT LAKE CITY, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (the “Company” or “Myriad…
Myriad Genetics proposes offering of $100M of shares of common stock
…
Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday By Benzinga
Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday…
Myriad Genetics, Inc. (MYGN) Q3 2023 Earnings Call Transcript
…
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q3
Myriad Genetics (MYGN) third-quarter 2023 revenues increase year over year, driven by strong testing volume improvement across all its businesses.…
Global Hereditary Testing Market Size To Worth USD 13.14 Billion By 2032 | CAGR of 7.8%
The Global Hereditary Testing Market Size was valued at USD 6.20 Billion in 2022 and the Worldwide Hereditary Testing Market…
Myriad Genetics Appoints Sam Raha as Chief Operating Officer
SALT LAKE CITY, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
QIAGEN N.V.: QIAGEN und Myriad Genetics schließen Partnerschaft und treiben Entwicklung von Begleitdiagnostika für Krebs voran
Partnerschaft umfasst die Entwicklung von im Labor entwickelten (LDT) und vertriebsfähigen diagnostischen Begleittests auf Kit-Basis // Vereinte Stärken in den…
GNW-Adhoc: QIAGEN und Myriad Genetics schließen Partnerschaft und treiben Entwicklung von Begleitdiagnostika für Krebs voran
^Partnerschaft umfasst die Entwicklung von im Labor entwickelten (LDT) und vertriebsfähigen diagnostischen…
GlobeNewswire: QIAGEN und Myriad Genetics schließen Partnerschaft und treiben Entwicklung von Begleitdiagnostika für Krebs voran
QIAGEN und Myriad Genetics schließen Partnerschaft und treiben Entwicklung von Begleitdiagnostika für Krebs voran Partnerschaft umfasst die Entwicklung von im…
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only test Myriad can conduct prospective clinical…
Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer
Research will use Myriad’s high-definition MRD testing platform based on whole-genome sequencing Research will use Myriad’s high-definition MRD testing platform…
Myriad Genetics (MYGN) Teams Up to Assess Breast Cancer Risk
Myriad Genetics (MYGN) announces collaboration with Onsite Womens Health to develop a breast cancer risk assessment program....…
Myriad Genetics to Host Investor Day on September 19, 2023
SALT LAKE CITY, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Myriad Genetics (MYGN) Adds ARR to Prolaris Biomarker Test
Myriad Genetics (MYGN) announces the integration of ARR into the Prolaris prostate cancer prognostic test....…
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1...…
Myriad Genetics (MYGN) Unveils GeneSight Test Enhancement
Myriad Genetics (MYGN) GeneSight report will contain details on how a patients smoking history may affect their metabolism of certain…
Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status
SALT LAKE CITY, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing…
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss
Strong testing volume improvement across all businesses drives Myriad Genetics (MYGN) Q2 performance....…
Myriad Genetics Inc. Q2 Earnings Summary
WASHINGTON (dpa-AFX) - Below are the earnings highlights for Myriad Genetics Inc. (MYGN):Earnings: -$116.1 million in Q2 vs. -$14.1 million…
Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023
SALT LAKE CITY, July 27, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
RiskScore is the first validated risk model that includes breast density, personal/family history and genetic markers...…
Myriad Genetics announces $90M asset-based credit facility
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K MYRIAD GENETICS INC For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response Myriad to support MD Anderson…
Myriad Genetics to Participate in Goldman Sachs Healthcare Conference
SALT LAKE CITY, June 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Insiderhandel: Aufsichtsrat verkauft Aktien von Myriad Genetics im Wert von 198.760$
Spiegelman, Daniel K. - Aufsichtsrat - Tag der Transaktion: 2023-06-02...…
Form 8-K MYRIAD GENETICS INC For: Jun 01
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics
SALT LAKE CITY, May 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Myriad Genetics (MYGN) Adds New Test to Oncology Portfolio
Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test....…
Goldman Sachs Maintains Myriad Genetics Buy Recommendation
Goldman Sachs has maintained coverage of Myriad Genetics with a Buy recommendation....…
Goldman Sachs Upgrades Myriad Genetics
Goldman Sachs has upgraded its outlook for Myriad Genetics to Buy....…
Myriad Genetics rises as Goldman upgrades on growth potential
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Myriad Genetics Soars on Double Upgrade from Goldman
Analysts say they expect the company to be operating cash flow positive in 2023....…
Myriad Genetics Earns 2023 Great Place to Work Certification™
SALT LAKE CITY, May 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic…
Myriad Genetics Inc. Q1 Loss Increases, misses estimates
WASHINGTON (dpa-AFX) - Myriad Genetics Inc. (MYGN) announced Loss for its first quarter that increased from the same period last…
Myriad Genetics reports Q1 results, narrows FY 2023 guidance
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…